A new bioabsorbable sleeve for lung staple-line reinforcement (FOREsealTM):: report of a three-center phase II clinical trial

被引:15
|
作者
Thomas, Pascal
Massard, Gilbert
Porte, Henri
Doddoli, Christophe
Ducrocq, Xavier
Conti, Massimo
机构
[1] Univ Hosp Marseille, Dept Thorac Surg, Marseille, France
[2] Univ Hosp Strasbourg, Dept Thorac Surg, Strasbourg, France
[3] Univ Hosp Lille, Dept Thorac Surg, Lille, France
关键词
lung surgery; new technology;
D O I
10.1016/j.ejcts.2006.01.067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate on the feasibility, safety, and effectiveness of a new bioabsorbable material for lung staple-tine reinforcement. Methods: This prospective open trial included 66 patients (mean age of 56 +/- 17 years) who underwent various types of lung resection using staplers with knitted calcium alginate sleeves for buttressing (FOREseal (TM), Laboratoires Brothier, Nanterre, France) at three academic centers: 29 lobectomies, 22 emphysema surgeries, 15 wedge resections or lung biopsies. Intraoperative air leakage was assessed at a mean respiratory peak pressure of 30 cmH(2)O, and rated as grade 1, 2, or 3. Persistent air leakage in the postoperative course, as well as any relevant event, was assessed daily. The follow-up period was of 6 months. Results: No technical problem linked to the device occurred. Hemostasis of the cutting edges was completed in all patients. Fifty-six percent of the patients had no intraoperative air leak and 27.3% had grade 1 leaks. Mean postoperative air leaks and thoracic drainage times were 1.9 +/- 2.3 days and 6 +/- 5.3 days, respectively. In-hospital mortality was nit. There was no empyema. Mean hospital stay was 9.1 +/- 6.6 days. At follow-up, one patient underwent lung transplantation, and pathology of the explanted specimen showed the absence of device-related foreign-body inflammation. One patient complained from metalloptysis, and another one, with a metastatic invasive aspergillosis, developed an infectious recurrence that required reoperation. Conclusions: FOREseal is an ergonomic, safe, and promising new material instead of nonabsorbable materials and xenomaterials for staple-tine reinforcement. A randomized comparative study is now in progress. (c) 2006 Elsevier B.V. All. rights reserved.
引用
收藏
页码:880 / 885
页数:6
相关论文
共 50 条
  • [31] Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy
    Fortman, Dylan
    Wang, Hong
    Vanderweele, Robert
    Evans, Terry
    Herman, James G.
    Rhee, John
    Reyes, Vincent
    Mclaughlin, Brian
    Wozniak, Antoinette
    Somasundaram, Ashwin
    Mekhail, Tarek
    Socinski, Mark A.
    Schulze, Katja
    Villaruz, Liza C.
    CLINICAL LUNG CANCER, 2025, 26 (01) : 78 - 81
  • [32] Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
    He, Z.
    Xu, C.
    Chen, G.
    Wang, J.
    Zhang, X.
    Wang, P.
    Ma, T.
    Zhang, Y.
    Tian, C.
    Chen, Y.
    Zou, M.
    Han, Y.
    Wang, L.
    Ma, S.
    Chen, H.
    Wu, Y.
    Wu, X.
    Yang, S.
    Gao, Y.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S1395 - S1396
  • [33] An open, multi-center, phase II clinical trial to evaluate efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer preliminary report.
    Chao, Y
    Li, CP
    Chao, TY
    Su, WC
    Hsieh, RK
    Wu, MF
    Yeh, KH
    Chen, LT
    Cheng, AL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 346S - 346S
  • [34] PHASE II STUDY OF AMRUBICIN (AMR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AS THIRD-LINE OR FOURTH-LINE CHEMOTHERAPY: HOKKAIDO LUNG CANCER CLINICAL STUDY GROUP TRIAL (HOT) 0901
    Itoh, K.
    Harada, T.
    Takamura, K.
    Kikuchi, E.
    Ohizumi, S.
    Sugawara, S.
    Maemondo, M.
    Fujita, Y.
    Kinoshita, I.
    Inoue, A.
    Hommura, F.
    Katsuura, Y.
    Dosaka-Akita, H.
    Isobe, H.
    Nishimura, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 113 - 113
  • [35] Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer
    Xiao-hui Ge
    Qiang Lin
    Xiao-cang Ren
    Yue-e Liu
    Xue-ji Chen
    Dong-ying Wang
    Yong-qiang Wang
    Bin Cao
    Zhi-gang Li
    Miao-ling Liu
    Radiation Oncology, 8
  • [36] Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer
    Ge, Xiao-hui
    Lin, Qiang
    Ren, Xiao-cang
    Liu, Yue-e
    Chen, Xue-ji
    Wang, Dong-ying
    Wang, Yong-qiang
    Cao, Bin
    Li, Zhi-gang
    Liu, Miao-ling
    RADIATION ONCOLOGY, 2013, 8
  • [37] Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: Report of Japan Clinical Oncology Group Trial 9806
    Kunitoh, Hideo
    Kato, Harubumi
    Tsuboi, Masahiro
    Shibata, Taro
    Asamura, Hisao
    Ichonose, Yukito
    Katakami, Nobuyuki
    Nagai, Kanji
    Mitsudomi, Tetsuya
    Matsumura, Akihide
    Nakagawa, Ken
    Tada, Hirohito
    Saijo, Nagahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 644 - 649
  • [38] Integrative transcriptome analysis in patients in a phase II clinical trial of first-line erlotinib for clinically selected patients with advanced non-small cell lung cancer
    Laskin, Janessa J.
    Pugh, Trevor J.
    Jackson, Cathy
    Barclay, Lorena
    Morin, Ryan
    Ionescu, Diana
    Melosky, Barbara
    Cheryl, Ho
    Sun, Sophie
    Murray, Nevin R.
    Marra, Marco A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S328 - S329
  • [39] Anlotinib combined with s-1 in the third-line or later-line treatment of stage IV non-small cell lung cancer: Study for phase II clinical trial.
    Yang, Xiyue
    Du, Xiaobo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] A randomized phase II trial of pre-operative docetaxel and cisplatin (DP) or docetaxel alone (D) in clinical (c-) stage IB/II nonsmall cell lung cancer (NSCLC): Initial report of Japan Clinical Oncology Group trial (JCOG 0204)
    Tada, H
    Katoh, H
    Kunitoh, H
    Tsuboi, M
    Asamura, H
    Nagai, K
    Mitsudomi, T
    Koike, T
    Ishizuka, N
    Saijoh, N
    LUNG CANCER, 2005, 49 : S17 - S17